Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02186 LUYE PHARMA
RTNominal up2.690 +0.040 (+1.509%)
Others

01/11/2017 17:20

[I-bank focus]CS restarts Luye Pharma (02186) at HK$5.87

[ET Net News Agency, 1 November 2017] Credit Suisse assumed coverage on Luye Pharma
Group (02186) with a "neutral" rating from "outperform", and a lower target price of
HK$5.87 (from HK$6.3 perviously).
The research house sees that the company lacks short-term catalysts, after Lipusu
dropped out from the NDRL negotiation and Risperidone's approval expected to be achieved
in late 2019.
The company is currently trading at 15x 2018 P/E, 20% discounted to other HK-listed
names, which Credit Suisse believes has already factored in the pressures. The research
house adjusted down its sales forecast by 3%/5%/6% and EPS by 19%/18%/16% in 2017-19,
respectively. (KL)

Back to Others

Remark: Real time quote last updated: 24/04/2024 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.